Almujtama Alraida Medical Co. (9592.SR)
SAR 31.95
(2.4%)
SAR 31.95
(2.4%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 407.73 Million | 367.07 Million | 304.49 Million |
| Cost of Revenue | 278.53 Million | 270.39 Million | 242.89 Million |
| Gross Profit | 129.2 Million | 96.67 Million | 61.6 Million |
| Operating Expenses | 115.25 Million | 70.96 Million | 51.67 Million |
| Selling, General and Administrative Expenses | -278.53 Million | 70.96 Million | 51.67 Million |
| Research and Development Expenses | - | - | - |
| Other Expenses | 393.79 Million | 1.8 Million | 1.59 Million |
| Cost and Expenses | 393.79 Million | 341.36 Million | 294.56 Million |
| Operating Income | 13.94 Million | 25.71 Million | 9.93 Million |
| Interest Expense | 6.04 Million | 4.41 Million | 2.58 Million |
| Income Tax Expense | - | 2.09 Million | 507.34 Thousand |
| Earnings before Tax | 13.48 Million | 21.17 Million | 8.31 Million |
| Net Income | 11.39 Million | 19.07 Million | 7.81 Million |
| Earnings Per Share Basic | 1.20 | 2.01 | 0.82 |
| Earnings Per Share Diluted | 1.20 | 2.01 | 0.82 |
| Weighted Average Shares Outstanding | 9.49 Million | 9.5 Million | 9.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 9.49 Million | 9.5 Million | 9.5 Million |
| Gross Margin | 0.32 | 0.26 | 0.20 |
| EBIT Margin | 0.05 | 0.13 | 0.11 |
| Profit Margin | 0.03 | 0.05 | 0.03 |
| EBITDA | 19.53 Million | 47.74 Million | 34.51 Million |
| Earnings Before Tax Margin | 0.03 | 0.07 | 0.03 |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 209.39 Million | 203.6 Million | 407.74 Million | 204.13 Million | 367.07 Million | 195.27 Million |
| Cost of Revenue | 160.04 Million | 156.91 Million | 278.53 Million | 151.08 Million | 270.39 Million | 142.09 Million |
| Gross Profit | 49.35 Million | 46.68 Million | 129.2 Million | 53.04 Million | 96.67 Million | 53.17 Million |
| Operating Expenses | 45.73 Million | 45.9 Million | 115.25 Million | 39.88 Million | 70.96 Million | 38.58 Million |
| Selling, General and Administrative Expenses | 45.73 Million | 45.8 Million | - | 39.88 Million | - | 38.58 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | -100.54 Thousand | -115.25 Million | - | 1.8 Million | - |
| Cost and Expenses | 205.77 Million | 202.81 Million | 393.79 Million | 190.97 Million | 341.36 Million | 180.68 Million |
| Operating Income | 3.61 Million | 786.66 Thousand | 13.94 Million | 13.16 Million | 25.71 Million | 14.59 Million |
| Interest Expense | 3.75 Million | - | 6.04 Million | 2.58 Million | 4.41 Million | 1.51 Million |
| Income Tax Expense | 1.81 Million | 697.15 Thousand | -11.39 Million | 1.39 Million | 2.09 Million | 1.29 Million |
| Earnings before Tax | 3.79 Million | 757.62 Thousand | 13.48 Million | 12.73 Million | 21.17 Million | 13.52 Million |
| Net Income | 1.98 Million | 60.47 Thousand | 11.39 Million | 11.33 Million | 19.07 Million | 12.23 Million |
| Earnings Per Share Basic | 0.21 | 0.01 | - | 1.19 | - | 1.29 |
| Earnings Per Share Diluted | 0.21 | 0.01 | - | 1.19 | - | 1.29 |
| Weighted Average Shares Outstanding | 9.5 Million | 9.5 Million | 9.49 Million | 9.5 Million | 9.5 Million | 9.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 9.5 Million | 9.5 Million | 9.49 Million | 9.5 Million | 9.5 Million | 9.5 Million |
| Gross Margin | 0.24 | 0.23 | 0.32 | 0.26 | 0.26 | 0.27 |
| EBIT Margin | 0.11 | 0.08 | - | 0.13 | - | 0.14 |
| Profit Margin | 0.01 | 0.00 | 0.03 | 0.06 | 0.05 | 0.06 |
| EBITDA | 23.12 Million | 16.61 Million | - | 26.8 Million | - | 26.62 Million |
| Earnings Before Tax Margin | 0.02 | 0.00 | 0.03 | 0.06 | 0.07 | 0.07 |
CHIP
IBTA
4231
HLEE
TGR
PECN